Эффективность антиэпилептических препаратов новой генерации в терапии криптогенных и симптоматических фокальных форм эпилепсии у детей

Purpose. Comparison of the clinical efficiency of antiepileptic drugs of new generation — topiramate and lamotrigine — in treatment of symptomatic and cryptogenic focal forms of epilepsy in children. Material and methods. 2 groups of patients were included in research, aged from 2 to 17 years old, on 31 person in each group with symptomatic and cryptogenic focal forms of epilepsy. 1 group of patients were treated by topiramate in dozes from 56 up to 500 mg/day, from 2,8 mg/kg/day up to 17 mg/kg/day (on the average 6,6 mg/kg/day). Patients of the second group received therapy by lamotrigine in dozes from 25 mg/day up to 250 mg/day, from 0,5 mg/kg/day up to 6 mg/kg/day (on the average 3,6 mg/ kg/day). Treatment was in monotherapy and in combinations with others antiepileptic grugs. Results. Seizures freedom was achieved in 26% of patients in each groups. Reduction of seizures freqency more than 50% was observed in 61 % cases in topiramate group and in 45% of cases in lamotrigine group. Aggravation of myoclonic seizures was registered in 1 (3%) patient, used topiramate and in 2 (6%) patients used lamotrigine. Conclusion. Topiramate and lamotrigine have shown high clinical efficiency in treatment symptomatic and cryptogenic focal forms of epilepsy in children.